Article
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
Oncotarget - 22 Mar 2016
Kim Nayoung, Cho Ahye, Watanabe Hideo, Choi Yoon-La, Aziz Meraj, Kassner Michelle, Joung Je-Gun, Park Angela Kyung-Joo, Francis Joshua M, Bae Joon Seol, Ahn Soo-Min, Kim Kyoung-Mee, Park Joon Oh, Park Woong-Yang, Ahn Myung-Ju, Park Keunchil, Koo Jaehyung, Yin Hongwei Holly, Cho Jeonghee
Abstract excerpt
Therapies targeting the tyrosine kinase activity of Epidermal Growth Factor Receptor (EGFR) have been proven to be effective in treating a subset of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Inevitably these patients develop resistance to the EGFR-targeted tyrosine kinase inhibitors (TKIs). Here, we performed integrated genomic analyses using an in vitro system to uncover...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.